Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11300MR)

This product GTTS-WQ11300MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11300MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1945MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ6109MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ14800MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ1379MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ10310MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ2343MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ10016MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ15946MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW